Apellis Pharmaceuticals, Inc. $APLS Stock Holdings Raised by Profund Advisors LLC

Profund Advisors LLC grew its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 78.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 61,832 shares of the company’s stock after purchasing an additional 27,120 shares during the quarter. Profund Advisors LLC’s holdings in Apellis Pharmaceuticals were worth $1,553,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of APLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Apellis Pharmaceuticals by 207.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,559 shares of the company’s stock valued at $667,000 after buying an additional 19,944 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Apellis Pharmaceuticals by 26.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company’s stock worth $6,730,000 after buying an additional 64,742 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Apellis Pharmaceuticals by 4.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company’s stock worth $4,869,000 after buying an additional 9,747 shares during the last quarter. Focus Partners Wealth grew its position in shares of Apellis Pharmaceuticals by 118.4% in the 1st quarter. Focus Partners Wealth now owns 21,883 shares of the company’s stock worth $479,000 after acquiring an additional 11,862 shares in the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of Apellis Pharmaceuticals by 1,146.2% in the 1st quarter. Acadian Asset Management LLC now owns 23,976 shares of the company’s stock worth $522,000 after acquiring an additional 22,052 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Wall Street Zen raised Apellis Pharmaceuticals to a “hold” rating in a research report on Saturday, May 16th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Apellis Pharmaceuticals in a research note on Friday, May 15th. Wedbush dropped their target price on shares of Apellis Pharmaceuticals from $20.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. William Blair downgraded shares of Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Robert W. Baird lowered shares of Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Three equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $35.72.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ APLS opened at $41.03 on Thursday. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $41.14. The company has a market cap of $5.25 billion, a PE ratio of 40.23 and a beta of -0.24. The stock has a 50 day simple moving average of $34.03 and a 200-day simple moving average of $26.42. The company has a current ratio of 3.63, a quick ratio of 3.16 and a debt-to-equity ratio of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Thursday, May 7th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.29) by $0.44. Apellis Pharmaceuticals had a return on equity of 39.71% and a net margin of 12.06%.The firm had revenue of $268.30 million for the quarter, compared to analysts’ expectations of $208.91 million. On average, equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.14 EPS for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.